Alvotech turns to a CDMO's 40,000-liter Syracuse facility for biosimilar drug substance as it expands its manufacturing network.
|Articles|April 1, 2018
Experienced Service. Global Capabilities.
Eurofins Lancaster Laboratories provides testing services for all stages of the drug development process and supports all functional areas of bio/pharmaceutical manufacturing.
Advertisement
Eurofins Lancaster Laboratories provides testing services for all stages of the drug development process and supports all functional areas of bio/pharmaceutical manufacturing. We offer the flexibility to manage your testing programs through your choice of three unique service models, including standard Fee for Service, as well as our award-winning Professional Scientific Services® PSS insourcing solution® and Full-Time-Equivalent (FTE) service models.
CPhI North America Booth #1533
Advertisement
Related to this article
New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.
Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Advertisement
Advertisement